12:00 AM
 | 
Jun 22, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Anagrelide CR: Updated Phase II data

Updated data from an open-label, U.S. Phase II trial in 18 patients with elevated platelet counts secondary to essential thrombocythemia and other myeloproliferative neoplasms showed that twice-daily oral GALE-401 led to an overall response rate (ORR), the primary endpoint, of 78%, including 7 complete responses and 7 partial responses. A complete platelet...

Read the full 239 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >